VERV — Verve Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $555.23m
- -$68.72m
- $11.76m
- 51
- 17
- 18
- 18
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 18.8 | 72.1 | 360 | 555 | 624 |
Net Total Receivables | — | — | — | 1.01 | 5.9 |
Prepaid Expenses | |||||
Total Current Assets | 19.1 | 74 | 367 | 563 | 638 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.36 | 3.98 | 9.06 | 111 | 108 |
Other Long Term Assets | |||||
Total Assets | 21.6 | 78.4 | 384 | 679 | 753 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.55 | 7.32 | 22 | 35.1 | 37 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 15.7 | 17.2 | 26.8 | 128 | 153 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Total Equity | 5.93 | 61.3 | 357 | 551 | 600 |
Total Liabilities & Shareholders' Equity | 21.6 | 78.4 | 384 | 679 | 753 |
Total Common Shares Outstanding |